Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Zentralbl Chir ; 141(4): 383-9, 2016 Aug.
Artigo em Alemão | MEDLINE | ID: mdl-25333520

RESUMO

BACKGROUND: Survival time is an important parameter to investigate therapeutic measures. It plays a crucial role in study concepts, data analyses as well as publications. AIM: The aim of this study was to emphasise essential points, which need to be taken into account to (i) gain resilient results of survival time analysis and (ii) appropriately evaluate scientific reports. Corner Points/Main Statements: (i) The main analytical methods are Kaplan-Meier procedure to estimate survival time curves, the log rank test to compare two or more survival curves from independent samples and Cox regression for comparisons under simultaneous consideration of several influencing factors. (ii) Dependent relationships between survival and censoring probabilities may falsify these statistical procedures. (iii) For several end points, which need to be differentiated (such as death, progression etc.), and for interdependent sample elements, extended statistical procedures such as competing risk analyses or extended Cox regression models are available. CONCLUSION: Survival time analysis can be considered as being extraordinarily important for evaluation of data obtained in therapeutic studies. For the academic and publishing physician, in particular, for the clinical surgeon, a basic understanding of these methodological aspects in statistics is indispensable.


Assuntos
Procedimentos Cirúrgicos Operatórios/mortalidade , Análise de Sobrevida , Progressão da Doença , Humanos , Estimativa de Kaplan-Meier , Modelos de Riscos Proporcionais , Editoração/estatística & dados numéricos , Fatores de Risco
2.
Stat Med ; 30(26): 3067-81, 2011 Nov 20.
Artigo em Inglês | MEDLINE | ID: mdl-21898523

RESUMO

This paper discusses the application of an adaptive design for treatment arm selection in an oncology trial, with survival as the primary endpoint and disease progression as a key secondary endpoint. We carried out treatment arm selection at an interim analysis by using Bayesian predictive power combining evidence from the two endpoints. At the final analysis, we carried out a frequentist statistical test of efficacy on the survival endpoint. We investigated several approaches (Bonferroni approach, 'Dunnett-like' approach, a conditional error function approach and a combination p-value approach) with respect to their power and the precise conditions under which type I error control is attained.


Assuntos
Ensaios Clínicos Fase II como Assunto/estatística & dados numéricos , Ensaios Clínicos Fase III como Assunto/estatística & dados numéricos , Neoplasias Pulmonares/tratamento farmacológico , Terapia de Alvo Molecular/estatística & dados numéricos , Seleção de Pacientes , Projetos de Pesquisa/estatística & dados numéricos , Teorema de Bayes , Simulação por Computador , Tomada de Decisões , Humanos , Modelos Estatísticos , Análise de Sobrevida , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA